Obesity management in the Saudi population

Article Figures & Data

Table 1

- Pharmacotherapy used in obesity management.

Drugs	Starting doses	Available doses	Side effects	Contraindications
Orlistat	120mg TDS	120 mg	Steatorrhea, oil spots, faecal incontinence, fat-soluble vitamin malabsorption, and flatulence with discharge	Pregnancy
Liraglutide	0.6 mg	0.6-3mg	Nausea, vomiting, diarrhoea, constipation, pancreatitis (rare), and cholecystitis (rare)	Severe renal or hepatic insufficiency, pregnancy, history of pancreatitis, and psychiatric disorder
Lorcaserin	10 mg BID	10 mg	Dry mouth, dizziness, somnolence, headache, and gastrointestinal disturbances	Severe renal insufficiency or severe hepatic impairment, pregnant
Phenteramine/topiramate	15 mg/12.5 mg	Phe-15 mg Topi-12.5, 25, 50, 100 mg	Dry mouth, insomnia, agitation, constipation, and tachycardia	Severe hypertension, cardiovascular disease, glaucoma, history of drug or alcohol abuse, monoamine oxidase inhibitors, selective serotonin reuptake inhibitor use, and pregnancy
Natrexone/bupropion	8 mg/90 mg	Nal-8 mg Bup-90 mg	Constipation, diarrhoea, nausea, vomiting, dizziness, and anxiety	Acute opiate withdrawal, allergy to bupropion, bulimia, anorexia nervosa, history of seizure disorder, and uncontrolled hypertension
Semaglutide	0.25 mg SQ once weekly then titrate	2.4 mg	Hypoglycaemia, abdominal pain, constipation, and nausea	Personal or family history of medullary thyroid carcinoma, known hypersensitivity to semaglutide